Photocure (PHO) Stock Overview
Engages in the research, development, production, distribution, marketing, and sale of pharmaceutical products. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 1/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
PHO Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Photocure ASA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NOK 58.90 |
| 52 Week High | NOK 79.80 |
| 52 Week Low | NOK 49.50 |
| Beta | 0.36 |
| 1 Month Change | -10.62% |
| 3 Month Change | -15.74% |
| 1 Year Change | 14.37% |
| 3 Year Change | 17.10% |
| 5 Year Change | -60.39% |
| Change since IPO | -68.67% |
Recent News & Updates
Recent updates
Photocure's (OB:PHO) Promising Earnings May Rest On Soft Foundations
Photocure ASA's ( OB:PHO ) robust earnings report didn't manage to move the market for its stock. We did some digging...Photocure ASA (OB:PHO) Stock Rockets 29% But Many Are Still Ignoring The Company
Photocure ASA ( OB:PHO ) shares have had a really impressive month, gaining 29% after a shaky period beforehand. Taking...Photocure ASA (OB:PHO) Could Be Riskier Than It Looks
It's not a stretch to say that Photocure ASA's ( OB:PHO ) price-to-sales (or "P/S") ratio of 2.6x seems quite...
Advancements In BLC Technology And Hexvix Launch Will Revolutionize Bladder Cancer Diagnosis
Strategic initiatives in the U.S. and Europe, such as Blue Light Cystoscopy expansion and partnerships, are expected to drive significant revenue and market growth.Photocure ASA's (OB:PHO) Shares Leap 29% Yet They're Still Not Telling The Full Story
Photocure ASA ( OB:PHO ) shareholders would be excited to see that the share price has had a great month, posting a 29...We Think Photocure's (OB:PHO) Robust Earnings Are Conservative
Photocure ASA ( OB:PHO ) just reported healthy earnings but the stock price didn't move much. We think that investors...Photocure ASA's (OB:PHO) P/S Still Appears To Be Reasonable
It's not a stretch to say that Photocure ASA's ( OB:PHO ) price-to-sales (or "P/S") ratio of 3.5x right now seems quite...Photocure ASA's (OB:PHO) 26% Jump Shows Its Popularity With Investors
Despite an already strong run, Photocure ASA ( OB:PHO ) shares have been powering on, with a gain of 26% in the last...Potential Upside For Photocure ASA (OB:PHO) Not Without Risk
You may think that with a price-to-sales (or "P/S") ratio of 2.7x Photocure ASA ( OB:PHO ) is a stock worth checking...Time To Worry? Analysts Just Downgraded Their Photocure ASA (OB:PHO) Outlook
One thing we could say about the analysts on Photocure ASA ( OB:PHO ) - they aren't optimistic, having just made a...Shareholder Returns
| PHO | NO Pharmaceuticals | NO Market | |
|---|---|---|---|
| 7D | -5.0% | -3.0% | 0.2% |
| 1Y | 14.4% | 7.2% | 18.3% |
Return vs Industry: PHO exceeded the Norwegian Pharmaceuticals industry which returned 7% over the past year.
Return vs Market: PHO underperformed the Norwegian Market which returned 18.3% over the past year.
Price Volatility
| PHO volatility | |
|---|---|
| PHO Average Weekly Movement | 8.0% |
| Pharmaceuticals Industry Average Movement | 5.3% |
| Market Average Movement | 5.4% |
| 10% most volatile stocks in NO Market | 11.4% |
| 10% least volatile stocks in NO Market | 3.2% |
Stable Share Price: PHO's share price has been volatile over the past 3 months compared to the Norwegian market.
Volatility Over Time: PHO's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of Norwegian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | 100 | Dan Schneider | www.photocure.com |
Photocure ASA, together with its subsidiaries, engages in the research, development, production, distribution, marketing, and sale of pharmaceutical products. It operates through two segments, Commercial Franchise and Development Portfolio. The company offers Hexvix/Cysview for the detection and management of bladder cancer.
Photocure ASA Fundamentals Summary
| PHO fundamental statistics | |
|---|---|
| Market cap | NOK 1.57b |
| Earnings (TTM) | NOK 84.31m |
| Revenue (TTM) | NOK 671.85m |
Is PHO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PHO income statement (TTM) | |
|---|---|
| Revenue | NOK 671.85m |
| Cost of Revenue | NOK 43.20m |
| Gross Profit | NOK 628.65m |
| Other Expenses | NOK 544.34m |
| Earnings | NOK 84.31m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
Jul 29, 2026
| Earnings per share (EPS) | 3.17 |
| Gross Margin | 93.57% |
| Net Profit Margin | 12.55% |
| Debt/Equity Ratio | 0% |
How did PHO perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/05 03:35 |
| End of Day Share Price | 2026/06/05 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Photocure ASA is covered by 4 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | Brookline Capital Markets |
| Geir Holom | DNB Carnegie |
| Maxim Jacobs | Edison Investment Research |